107 related articles for article (PubMed ID: 21753034)
1. Sensorineural hearing loss following imatinib (Gleevec) administration.
Lin HW; Roberts DS; Kay J; Stankovic KM
Otolaryngol Head Neck Surg; 2012 Feb; 146(2):335-7. PubMed ID: 21753034
[No Abstract] [Full Text] [Related]
2. Irreversible sensorineural hearing loss due to Imatinib.
Attili VS; Bapsy PP; Anupama G; Lokanatha D
Leuk Res; 2008 Jun; 32(6):991-2. PubMed ID: 18221994
[TBL] [Abstract][Full Text] [Related]
3. Severe dental erosion associated with imatinib mesylate therapy.
Kyriazoglou A; Christopoulos C
Acta Oncol; 2014 Jul; 53(7):988-90. PubMed ID: 24446745
[No Abstract] [Full Text] [Related]
4. Pityriasis rubra pilaris-like reaction induced by imatinib.
Plana A; Carrascosa JM; Vilavella M; Ferrandiz C
Clin Exp Dermatol; 2013 Jul; 38(5):520-2. PubMed ID: 23777493
[TBL] [Abstract][Full Text] [Related]
5. Generic imatinib: the real-deal or just a deal?
Mathews V
Leuk Lymphoma; 2014 Dec; 55(12):2678-80. PubMed ID: 24798742
[No Abstract] [Full Text] [Related]
6. [Chronic myelogenous leukemia: management of treatment-related adverse events].
Takahashi N
Rinsho Ketsueki; 2012 Oct; 53(10):1581-8. PubMed ID: 23037730
[No Abstract] [Full Text] [Related]
7. [Imatinib for pulmonary arterial hypertension].
Hoeper MM; Opitz C; Olschewski H; Ulrich S; Speich R; Behr J; Halank M; Wilkens H; Klose H; Lange TJ; Grünig E; Seeger W; Ewert R; Borst MM; Welte T; Rosenkranz S; Ghofrani HA
Dtsch Med Wochenschr; 2014 Dec; 139 Suppl 4():S151-4. PubMed ID: 25489685
[No Abstract] [Full Text] [Related]
8. Imatinib in neurofibromatosis type 2.
Lim S; de Souza P
BMJ Case Rep; 2013 Jul; 2013():. PubMed ID: 23839611
[TBL] [Abstract][Full Text] [Related]
9. Incidence of spontaneous subdural hematoma in incident cases of pulmonary arterial hypertension: a registry of cases occurring over a five-year period.
Prada LF; Gavilanes F; Souza R
J Bras Pneumol; 2015; 41(1):101-2. PubMed ID: 25750681
[No Abstract] [Full Text] [Related]
10. Loss of skin pigment caused by imatinib therapy.
McPartlin S; Leach M
Br J Haematol; 2005 May; 129(4):448. PubMed ID: 15877727
[No Abstract] [Full Text] [Related]
11. Long-term molecular remission with persistence of BCR-ABL1-specific cytotoxic T cells following imatinib withdrawal in an elderly patient with Philadelphia-positive ALL.
Riva G; Luppi M; Lagreca I; Barozzi P; Quadrelli C; Vallerini D; Zanetti E; Basso S; Forghieri F; Morselli M; Maccaferri M; Paolini A; Fantuzzi V; Messerotti A; Maffei R; Iacobucci I; Martinelli G; Marasca R; Narni F; Comoli P; Potenza L
Br J Haematol; 2014 Jan; 164(2):299-302. PubMed ID: 24134676
[No Abstract] [Full Text] [Related]
12. Partial fanconi syndrome induced by imatinib therapy: a novel cause of urinary phosphate loss.
François H; Coppo P; Hayman JP; Fouqueray B; Mougenot B; Ronco P
Am J Kidney Dis; 2008 Feb; 51(2):298-301. PubMed ID: 18215707
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic inhibition of tyrosine kinases in systemic sclerosis: a review of published experience on the first 108 patients treated with imatinib.
Bournia VK; Evangelou K; Sfikakis PP
Semin Arthritis Rheum; 2013 Feb; 42(4):377-90. PubMed ID: 22789835
[TBL] [Abstract][Full Text] [Related]
14. Periungual pyogenic granuloma following imatinib therapy in a patient with chronic myelogenous leukemia.
Dika E; Barisani A; Vaccari S; Fanti PA; Ismaili A; Patrizi A
J Drugs Dermatol; 2013 May; 12(5):512-3. PubMed ID: 23652942
[No Abstract] [Full Text] [Related]
15. High-dose imatinib versus high-dose imatinib in combination with intermediate-dose cytarabine in patients with first chronic phase myeloid leukemia: a randomized phase III trial of the Dutch-Belgian HOVON study group.
Thielen N; van der Holt B; Verhoef GE; Ammerlaan RA; Sonneveld P; Janssen JJ; Deenik W; Falkenburg JH; Kersten MJ; Sinnige HA; Schipperus M; Schattenberg A; van Marwijk Kooy R; Smit WM; Chu IW; Valk PJ; Ossenkoppele GJ; Cornelissen JJ
Ann Hematol; 2013 Aug; 92(8):1049-56. PubMed ID: 23572137
[TBL] [Abstract][Full Text] [Related]
16. Imatinib as a possible cause of severe rhabdomyolysis.
Penel N; Blay JY; Adenis A
N Engl J Med; 2008 Jun; 358(25):2746-7. PubMed ID: 18565874
[No Abstract] [Full Text] [Related]
17. Imatinib and altered bone and mineral metabolism.
Tournis S; Lyritis GP
N Engl J Med; 2006 Aug; 355(6):627; author reply 628-9. PubMed ID: 16906646
[No Abstract] [Full Text] [Related]
18. Chronic myeloid leukemia and risk of second malignancy in two eras of treatment.
Stein BL
Leuk Lymphoma; 2012 Sep; 53(9):1651-3. PubMed ID: 22360717
[No Abstract] [Full Text] [Related]
19. Imatinib-induced Stevens-Johnson syndrome: recurrence after re-challenge with a lower dose.
Mahapatra M; Mishra P; Kumar R
Ann Hematol; 2007 Jul; 86(7):537-8. PubMed ID: 17287945
[No Abstract] [Full Text] [Related]
20. [Adverse effects of imatinib mesylate].
Isshiki I
Nihon Rinsho; 2007 Jan; 65 Suppl 1():404-7. PubMed ID: 17474438
[No Abstract] [Full Text] [Related]
[Next] [New Search]
